Key Decisions in HIV Care: Data on Long-Acting Injectable PrEP
Mar 14, 2022•18 min•Ep. 144
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
In this episode, Jason Schafer, PharmD, MPH, explores the data for long-acting injectable pre-exposure prophylaxis (PrEP).
Listen as he gives his perspectives on the:
- PrEP pipeline and the importance of having options for patients with differing preferences
- FDA approval of long-acting cabotegravir for PrEP
- HPTN 083 and 084 studies of long-acting cabotegravir for PrEP compared with oral emtricitabine/tenofovir disoproxil fumarate
- Safety data on long-acting cabotegravir for PrEP
- CDC recommendations on the management of injection-site reactions with cabotegravir for PrEP
Presenter:
Jason Schafer, PharmD, MPH
Professor and Vice Chair
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania
Follow along with the slides at:
https://bit.ly/3tbvEPK
See the entire program at:
https://bit.ly/3q2DlGd
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
For the best experience, listen in Metacast app for iOS or Android